
CytoSorbents (CTSO) Stock Forecast & Price Target
CytoSorbents (CTSO) Analyst Ratings
Bulls say
CytoSorbents Corp has demonstrated strong financial performance, with fourth quarter gross margins projected to range between 73% and 75%, and a full-year gross margin improvement to approximately 72%, highlighting the company's operational efficiency and manufacturing advancements. The company reported a year-over-year revenue increase of 10%, reaching $9.5 million, further supported by robust distributor-driven sales and expansion into international markets outside of Germany. Positive developments, including promising clinical data and a strengthened liquidity position through an amended credit agreement, underscore CytoSorbents' trajectory towards profitability and long-term growth potential.
Bears say
CytoSorbents Corp reported fourth-quarter revenue of approximately $9.2 million, which remained flat year-over-year, and a full-year revenue of around $37.0 million, reflecting only about 4% growth compared to the prior year. Management pointed out challenges such as patient imbalances that may hinder growth prospects in the U.S. market. The company's stock appears to be trading at a distressed valuation, which analysts believe is not aligned with its underlying fundamentals.
This aggregate rating is based on analysts' research of CytoSorbents and is not a guaranteed prediction by Public.com or investment advice.
CytoSorbents (CTSO) Analyst Forecast & Price Prediction
Start investing in CytoSorbents (CTSO)
Order type
Buy in
Order amount
Est. shares
0 shares